Databases Reference
In-Depth Information
Tabl e 4 .
Attributes for gene mapping used in both decision trees
Attribute no.
Gene description
2,288
DF D component of complement (adipsin)
461
Liver mRNA for interferon-gamma inducing factor (IGIF)
4,847
Zyxin X95735 at
6,281
MYL1 Myosin light chain (alkali)
1,779
MPO Myeloperoxidase
4,951
Nucleoside-diphosphate kinase
Tabl e 5 .
Rules for Leukemia classification derived from CMM decision tree
1. IF (zyxin X95735 NOT EXPRESSED) AND
(MYL1 Myosin Light Chain EXPRESSED)
⇒
ALL
2. IF (zyxin X95735 NOT EXPRESSED) AND
(MYL1 Myosin Light Chain (Alkali) NOT EXPRESSED) AND
(Nucleoside-diphosphate kinase EXPRESSED)
⇒
AML
3. IF (zyxin X95735 EXPRESSED) AND
(MPO Myeloperoxidase EXPRESSED)
⇒
AML
4 Discussion and Conclusion
Acute leukemia which is of lymphoid origin is called Acute Lymphocytic
Leukemia (ALL) and a malignant disorder where myeloid blast cells accu-
mulate in the marrow and bloodstream is called Acute Myelocytic Leukemia
(AML). A study conducted by Golub et al. [21] has revealed 50 predictive
genes that differentiate between ALL and AML. The report has shown that
over expression of myosin light chain (M31211) leads to the ALL. The re-
port also has indicated that zyxin 2 X95735, an adhesion plaque protein a
component of a signal transduction pathway that mediates adhesion stimu-
lated changes in gene expression, plays a significant role in AML. In a recent
study conducted by Umpai and Aitken [35] has demonstrated that the gene
X95735 zyxin significantly determines AML whereas myosin light chain over
expression frequency is higher in ALL patients. Some other studies also have
demonstrated the similar result. For example, Aris and Rece [36] has demon-
strated the differentiation technique of AML and ALL based on the fact that
zyxin is significant in AML, on the other hand, myosin light chain expression
is significant in ALL patients. The French-American-British (FAB) group [37]
has standardized the nature of ALL and AML on the basis of myeloperoxidase
(MPO) expression. According to the criteria, the AML group demonstrates
greater than 3% MPO and/or Sudan Black B (SBB) blast. The study has
also revealed that, 70-75% of AML cases show myeloid associated antigens
positive, for example, CD13, CD33, MPO etc., thus, it is evident that zyxin
